Final Results of the RHAPSODY Trial: A Multi‐Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A‐APC, A Recombinant Variant of Human Activated…

Overview of attention for article published in Annals of Neurology, January 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#24 of 6,674)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 57 news outlets
blogs: 4 blogs
twitter: 24 X users

wikipedia: 1 Wikipedia page
reddit: 1 Redditor

Readers on

mendeley: 139 Mendeley

So far, Altmetric has seen 24 X posts from 24 X users, with an upper bound of 44,233 followers.

RT @kaulcsmc: @DrToddLee @boback @ScienceMagazine RHAPSODY Trial: don't see mortality data reported! https://t.co/8J9YhJdfOx N=110 Mortali…

@DrToddLee @boback @ScienceMagazine RHAPSODY Trial: don't see mortality data reported! https://t.co/8J9YhJdfOx N=110 Mortality: 6/66 (9.1%) 3K3A-APC vs 1/44 (2.3%) placebo RR 4.0, 0.50-32.1, despite more pts in control received delayed tPA. Despite 3K3…

https://t.co/FDcn4taHTm https://t.co/uzGQeUeRXs https://t.co/yQRjbp7pl3 https://t.co/CmgEiZByN1 🔚

RHAPSODY was our Phase 2 clinical trial of 3K3A-APC in acute #ischemicstroke. Final results -> https://t.co/wNqE0jG9BX

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 20 additional X posts.